Mode
Text Size
Log in / Sign up
N/A Completed N=956

GreenLight XPS Laser System Retrospective Chart Review

Source: ClinicalTrials.gov NCT02139969 ↗
Enrolled (actual)
956
Serious AEs
1.4%
Results posted
Nov 2020
Primary outcomePrimary: International Prostate Symptom Score (IPSS) — 437; 118; 17 Participants

Summary

The purpose of this study is to gain information on the safety, efficacy, and quality of life in subjects who have had the GreenLight XPS procedure.

Outcome Measures

OutcomeResultp-value
PRIMARY
International Prostate Symptom Score (IPSS)
437; 118; 17
PRIMARY
Occurrence of Adverse Events Related to the Study Treatment.
249
SECONDARY
Characteristics of the Study Procedure
57.1; 33.2
SECONDARY
Characteristics of the Study Procedure and Immediate Outcomes
1.2
SECONDARY
Assess Changes in Quality of Life Related to BPH Symptoms.
1.3
SECONDARY
Assess Changes in Objective Measures of Urologic Function.
4.9; 2.6; -2.0
SECONDARY
Number of Participants With ER Visits, Hospital Admissions, and Surgical Re-treatments for Treatment-related Adverse Events Up to 90 Days Post-Procedure
39; 43; 14; 19; 4
SECONDARY
Evaluate the Percentage of Participants Experience Ongoing Treatment-related Urinary Incontinence
0.9; 0.9; 1.3; 1.1
SECONDARY
Assess the Occurrence of Surgical Retreatment for BPH in GreenLight XPS Patients.
4; 3
SECONDARY
Characteristics of the Study Procedure and Immediate Outcomes
1.2
SECONDARY
Length of Hospital Stay
0.5
SECONDARY
Type of Hospital Stay
674; 222; 58
SECONDARY
Number of Participants Stratified by Number of Fibers Used During Procedure
873; 76; 4
SECONDARY
Assess Changes in Objective Measures of Urologic Function
204.3; 46.1; -172
SECONDARY
Changes in Objective Measures of Urologic Function
76.0; 44.0; -31.8
SECONDARY
Assess Changes in Objective Measures of Urologic Function.
4.9; 2.6; -2.0

Eligibility Criteria

Inclusion Criteria

  • Men who have had a GreenLight XPS procedure with a MoXy Fiber since 01-Aug-2010.

Exclusion Criteria

  • Subject has had prior radiation.
  • Subject has a diagnosis of neurogenic bladder confirmed by urodynamic studies (BOO, detrusor overactivity (DO), impaired detrusor contractor (IDC))
  • Subject has a neurologic disorder that would impact bladder function (MS, Parkinson, Spinal Cord Injury) (note: Stroke patients not excluded)
  • Subject has an artificial urinary sphincter
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02139969). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search